ERBB2 and breast cancer: We confirmed that Bortezomib, similar to experimental tool agent thapsigargin, induced the ER stress in ErbB2-overexpressing breast cancer cell lines and that CHIP KD cells exhibited higher sensitivity to thapsigargin or Bortezomib (Figure 4D).